74 related articles for article (PubMed ID: 38607586)
1. RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.
Li B; Jin K; Liu Z; Su X; Xu Z; Liu G; Xu J; Chang Y; Wang Y; Zhu Y; Xu L; Wang Z; Liu H; Zhang W
J Immunother; 2024 May; ():. PubMed ID: 38800996
[TBL] [Abstract][Full Text] [Related]
2. Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy.
Meng J; Jiang A; Lu X; Gu D; Ge Q; Bai S; Zhou Y; Zhou J; Hao Z; Yan F; Wang L; Wang H; Du J; Liang C
Imeta; 2023 Nov; 2(4):e147. PubMed ID: 38868222
[TBL] [Abstract][Full Text] [Related]
3. Identification of CXCL13 as a Promising Biomarker for Immune Checkpoint Blockade Therapy and PARP Inhibitor Therapy in Ovarian Cancer.
Ding Y; Ye Z; Ding B; Feng S; Zhang Y; Shen Y
Mol Biotechnol; 2024 Jun; ():. PubMed ID: 38856873
[TBL] [Abstract][Full Text] [Related]
4. 2022 WUOF/SIU International Consultation on Urological Diseases: Genetics and Tumor Microenvironment of Renal Cell Carcinoma.
Khaleel S; Ricketts C; Linehan WM; Ball M; Manley B; Turajilic S; Brugarolas J; Hakimi A
Soc Int Urol J; 2022 Nov; 3(6):386-396. PubMed ID: 38840811
[TBL] [Abstract][Full Text] [Related]
5. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
[TBL] [Abstract][Full Text] [Related]
6. The expanding role of BAP1 in clear cell renal cell carcinoma.
Kapur P; Rajaram S; Brugarolas J
Hum Pathol; 2023 Mar; 133():22-31. PubMed ID: 35932824
[TBL] [Abstract][Full Text] [Related]
7. Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
[TBL] [Abstract][Full Text] [Related]
8. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
9. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.
Liu T; Xia Q; Zhang H; Wang Z; Yang W; Gu X; Hou T; Chen Y; Pei X; Zhu G; He D; Li L; Xu S
Aging (Albany NY); 2020 Nov; 12(21):21809-21836. PubMed ID: 33177244
[TBL] [Abstract][Full Text] [Related]
10. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
11. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Miao D; Margolis CA; Gao W; Voss MH; Li W; Martini DJ; Norton C; Bossé D; Wankowicz SM; Cullen D; Horak C; Wind-Rotolo M; Tracy A; Giannakis M; Hodi FS; Drake CG; Ball MW; Allaf ME; Snyder A; Hellmann MD; Ho T; Motzer RJ; Signoretti S; Kaelin WG; Choueiri TK; Van Allen EM
Science; 2018 Feb; 359(6377):801-806. PubMed ID: 29301960
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma.
Chen J; Yao C; Qiao N; Ge Y; Li J; Lin Y; Yao S
Cancer Med; 2021 Oct; 10(19):6590-6609. PubMed ID: 34535962
[TBL] [Abstract][Full Text] [Related]
13. HOOK1 Inhibits the Progression of Renal Cell Carcinoma via TGF-β and TNFSF13B/VEGF-A Axis.
Yin L; Li W; Chen X; Wang R; Zhang T; Meng J; Li Z; Xu L; Yin R; Cheng B; Yang H
Adv Sci (Weinh); 2023 Jun; 10(17):e2206955. PubMed ID: 37085921
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.
Rosellini M; Marchetti A; Mollica V; Rizzo A; Santoni M; Massari F
Nat Rev Urol; 2023 Mar; 20(3):133-157. PubMed ID: 36414800
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
